Active Pharmaceutical Ingredients
- Industrial Coatings
- Dyes and Pigments
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
- Analytical Chemistry
- Cosmetic Ingredient
- Pharmaceutical Intermediates
Epidemiological studies have shown a link between rheumatoid arthritis and Parkinson's disease (PD)
Disease-modifying antirheumatic drugs (DMARDs) may explain this association
Recently, a research article was published in Neurology, an authoritative journal in the field of neurology, to evaluate the relationship between DMARDs and PD risk in patients with rheumatoid arthritis
We performed a nested nationwide case-control study in the Finnish Parkinson's Disease (FINPARK) cohort, which included 22,189 Finns diagnosed
with PD between 1996-2015 .
These cases had a diagnosis of PD documented in a special reimbursement registry, and a diagnosis with symptoms that could be confused with PD was not excluded within two years of the diagnosis of PD
A total of 315 PD cases and 1571 matched controls were included
The majority (>60%) of patients were women, and the median duration of rheumatoid arthritis was 11.
CONCLUSIONS: The results of this study suggest that the use of DMARDs cannot explain the lower PD risk in patients with rheumatoid arthritis, as these drugs generally do not alter PD risk in patients with rheumatoid arthritis
The association between chloroquine/hydroxychloroquine and reduced risk of PD and possible underlying mechanisms should be further investigated
The results of this study suggest that the use of DMARDs cannot explain the lower risk of PD in patients with rheumatoid arthritis, as these drugs generally do not alter PD risk in patients with rheumatoid arthritis
Anne Paakinaho, et al.
RDisease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid ArthritisLeave a Comment here